Results 1 to 10 of about 2,667 (188)

Ravulizumab exposure in early pregnancy [PDF]

Annals of Hematology
Before complement inhibitors were available, pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) was associated with considerable mortality, mainly due to thromboembolism.
Wolfgang Füreder, Sonja Granser, Andreas Repa, Alex Farr   +3 more
doaj   +3 more sources

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome [PDF]

Journal of Comparative Effectiveness Research, 2023
Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden.
Teri J Mauch, Michael R Chladek, Spero Cataland, Shruti Chaturvedi, Bradley P Dixon, Katherine Garlo, Anuja Java, Jorge Leguizamo, Lucy Lloyd-Price, Tan P Pham, Tara Symonds, Ioannis Tomazos, Yan Wang   +12 more
doaj   +3 more sources

Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab [PDF]

Kidney International Reports
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a progressive rare disease that, if untreated, can result in severe organ damage and death.
Franz Schaefer, Imad Al-Dakkak, Katerina Anokhina, David Cohen, Larry A. Greenbaum, Gema Ariceta   +5 more
doaj   +3 more sources

Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study [PDF]

Annals of Hematology
Ravulizumab is a second-generation C5i engineered from eculizumab to achieve immediate, complete, and sustained inhibition of terminal complement activity in PNH.
Anna Paola Iori, Antonio De Vivo, Eros Di Bona, Giovanni Caocci, Francesca Fioritoni, Fabio Ciceri, Eloise Beggiato, Davide Rapezzi, Angela Amendola, Amalia Figuera, Carmine Selleri, Francesco Longu, Bruno Fattizzo, Alessandra Tucci, Alessandro Cignetti, Valeria Amico, Simona Sica, Elisabetta Metafuni, Simona Raso, Tiziana Anna Urbano, Luana Marano, Nicola Di Renzo, Pierangelo Spedini, Alessandro Rambaldi, Francesco Lanza, Cristina Clissa, Cristina Danesin, Maria Bruna Greve, Sergio Cabibbo, Alessandra Ori, Francesca Cassanelli, Federica Sottana, Benedetta Campolo, Giulia Gasparri, Fabio Carini, Wilma Barcellini   +35 more
doaj   +2 more sources

Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment [PDF]

Blood Advances
: In patients with paroxysmal nocturnal hemoglobinuria (PNH), the complement component 5 (C5) inhibitors ravulizumab and eculizumab control terminal complement activity and intravascular hemolysis, which are drivers of morbidity and mortality.
Austin G. Kulasekararaj, Jong Wook Lee, Christopher J. Patriquin, Caroline I. Piatek, Alexander Röth, Wilma Barcellini, Robert A. Brodsky, Jun-ichi Nishimura, Ji Yu, Mohammed Mahdi, Régis Peffault de Latour   +10 more
doaj   +2 more sources

Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice [PDF]

Frontiers in Neurology
PurposeTo describe the early experience of ravulizumab use in acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR+ve gMG).MethodsThis multicenter retrospective study included AChR+ve gMG patients who were treated with ravulizumab
Nakul Katyal, Raghav Govindarajan, Neelam Goyal, Suraj Muley, Srikanth Muppidi   +4 more
doaj   +3 more sources

Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study) [PDF]

Kidney Medicine
Rationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab, a complement C5 inhibitor (C5i), is approved for aHUS; however, published evidence in
Ramy Magdy Hanna, Shruti Chaturvedi, Moh-Lim Ong, Arpita Nag, Rui Song, Lynn Huynh, Jordan A. Burdeau, Mei Sheng Duh, Yan Wang   +8 more
doaj   +2 more sources

Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report [PDF]

BMJ Neurology Open
Background Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system (CNS). Management during pregnancy is challenging due to limited safety data for disease-modifying therapies.Case presentation ...
Anu Jacob, Azza Mahmoud, Luai Eldweik, Asia Mubashir   +3 more
doaj   +2 more sources

Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis. [PDF]

Clin Transplant
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a disease of complement dysregulation that may lead to kidney failure. Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of aHUS.
Gaeckler A, Al-Dakkak I, Saval N, Dieperink HH, Eygenraam M, Greenbaum LA, Isbel N, Walle JV.   +7 more
europepmc   +3 more sources

Analysis of adverse drug reactions associated with ravulizumab: a retrospective pharmacovigilance study utilizing the FAERS database [PDF]

Frontiers in Immunology
BackgroundRavulizumab is a long-acting C5 complement inhibitor that provides sustained suppression of the complement pathway. It is currently approved by the US Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis ...
Yue Zhou, Yutong Wu, Yingchao Su, Zhaoyou Meng   +3 more
doaj   +2 more sources